ALAUNOS THERAPEUTICS INC TCRT
COM NEW · Common Stock · CUSIP 98973P309
Immuno-oncology company
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersFort Lauderdale, FL
- Founded2004
- Websitealaunos.com
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 2.5m as of 2026-08-14, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $2.26.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q2 2024 | 3 |
| Q3 2024 | 30 |
| Q4 2024 | 31 |
| Q1 2025 | 30 |
| Q2 2025 | 29 |
| Q3 2025 | 26 |
| Q4 2025 | 27 |
| Q1 2026 | 29 |
| Q2 2026 | 29 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q3 2024 | 28 | 3 |
| Q4 2024 | 8 | 17 |
| Q1 2025 | 7 | 9 |
| Q2 2025 | 6 | 11 |
| Q3 2025 | 7 | 12 |
| Q4 2025 | 8 | 11 |
| Q1 2026 | 9 | 6 |
| Q2 2026 | 12 | 7 |
Biggest buyers
| CITADEL ADVISORS LLC | Added | +1.4k |
| Arax Advisory Partners | New | +1.2k |
| WELLS FARGO & COMPANY/MN | Added | +198 |
| ROYAL BANK OF CANADA | Added | +190 |
| MORGAN STANLEY | Added | +183 |
| BOKF, NA | New | +66 |
| Axiom Investment Management LLC | New | +46 |
| Tower Research Capital LLC (TRC) | Added | +38 |
| Steward Partners Investment Advisory, LLC | Added | +20 |
| BARCLAYS PLC | New | +15 |
Biggest sellers
| HRT FINANCIAL LP | Sold out | -13.3k |
| TWO SIGMA INVESTMENTS, LP | Sold out | -10.8k |
| XTX Topco Ltd | Sold out | -10.2k |
| GEODE CAPITAL MANAGEMENT, LLC | Reduced | -3.2k |
| UBS Group AG | Reduced | -1.3k |
| OSAIC HOLDINGS, INC. | Reduced | -48 |
| CITIGROUP INC | Sold out | -1 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
Fairmount Funds Management LLC
13D · may seek influence
new · filed 2026-10-15
Stated purposeThe Reporting Persons own 19.99% of the Company in the aggregate, based upon the Company's aggregate outstanding shares as of September 30, 2026, plus the shares of Common Stock issued in the Financing (as defined below). The Reporting Persons' securities include (i) 687,789 shares of Common Stock and (ii) 171,000 shares of Common Stock issuable upon conversion of 171 shares of Series C Preferred Stock held directly by Co-Invest and exclude (i) 105,286,000 shares of Common Stock issuable upon conversion of 105,286 shares of Series B Preferred Stock held directly by Fund II, (ii) 52,239,000 shares of Common Stock issuable upon conversion of 52,239 shares of the Series C Preferred Stock held directly by Fund II and (iii) 16,554,000 shares of Common Stock issuable upon conversion of 16,554 sh… Full filing |
20.0% |
| Postma Robert W 13D · may seek influence +1.0 pts · filed 2026-10-15 | 10.0% |
Price Adrian
13D · may seek influence
no change · filed 2026-03-05
Stated purposeOn February 24, 2026, counsel for Adrian Price sent a letter on behalf of the Reporting Persons to counsel of Alaunos Therapeutics, Inc. (the "Company"), and requested that the Company's counsel provide the letter to the Company's Board of Directors ("Board"). In this letter, Mr. Price proposed a private placement whereby HexagonONE Ltd, Alimenta Holding Limited and Krakatau Holding Limited (the "Investors") would purchase $7,000,000 of securities of the Company subject to mutually agreeable definitive documentation and customary closing conditions. The securities purchased by the Investors would be equity or equity-linked securities, with the purchase price to be negotiated in good faith, taking into account market conditions, the Company's liquidity needs, and long-term shareholder alig… Full filing |
8.6% |
Insider purchases and sales since 1 Apr 2026
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q4 2024 | 0 | — | 1 | $6.0k | — |
| Q1 2025 | 0 | — | 0 | — | — |
| Q2 2025 | 0 | — | 0 | — | — |
| Q3 2025 | 0 | — | 0 | — | — |
| Q4 2025 | 0 | — | 0 | — | — |
| Q1 2026 | 0 | — | 0 | — | — |
| Q2 2026 | 0 | — | 0 | — | — |
| Q3 2026 | 0 | — | 0 | — | — |
None reported since 1 Apr 2026.
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc. 0.00% of their portfolio | 21.4k $48.3k | Unchanged |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 19.4k $43.8k | Reduced -3.2k |
| VANGUARD FIDUCIARY TRUST CO 0.00% of their portfolio | 15.5k $35.0k | Unchanged |
| VANGUARD CAPITAL MANAGEMENT LLC 0.00% of their portfolio | 14.1k $31.8k | Unchanged |
| CITADEL ADVISORS LLC 0.00% of their portfolio | 11.9k $26.8k | Added +1.4k |
| OSAIC HOLDINGS, INC. 0.00% of their portfolio | 1.7k $3.9k | Reduced -48 |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 1.6k $3.7k | Added +38 |
| Arax Advisory Partners 0.00% of their portfolio | 1.2k $2.7k | New |
| UBS Group AG 0.00% of their portfolio | 992 $2.2k | Reduced -1.3k |
| MORGAN STANLEY 0.00% of their portfolio | 836 $1.9k | Added +183 |
| Vanguard Global Advisers, LLC 0.00% of their portfolio | 501 $1.1k | Unchanged |
| WELLS FARGO & COMPANY/MN 0.00% of their portfolio | 388 $877 | Added +198 |
| ROYAL BANK OF CANADA 0.00% of their portfolio | 375 $1.0k | Added +190 |
| Blue Trust, Inc. 0.00% of their portfolio | 135 $305 | Unchanged |
| Steward Partners Investment Advisory, LLC 0.00% of their portfolio | 112 $253 | Added +20 |
| Federation des caisses Desjardins du Quebec 0.00% of their portfolio | 70 $158 | Unchanged |
| BOKF, NA 0.00% of their portfolio | 66 $149 | New |
| Axiom Investment Management LLC 0.00% of their portfolio | 46 $104 | New |
| Key Financial Inc 0.00% of their portfolio | 24 $54 | Unchanged |
| SIGNATUREFD, LLC 0.00% of their portfolio | 23 $52 | Unchanged |
| NFSG Corp 0.00% of their portfolio | 21 $47 | Unchanged |
| LANARK FINANCIAL, INC. 0.00% of their portfolio | 20 $45 | Unchanged |
| AdvisorNet Financial, Inc 0.00% of their portfolio | 19 $43 | Unchanged |
| BARCLAYS PLC 0.00% of their portfolio | 15 $34 | New |
| WEST PACES ADVISORS INC. 0.00% of their portfolio | 10 $23 | New |
| Inspire Investing, LLC 0.00% of their portfolio | 9 $20 | Unchanged |
| BNP PARIBAS FINANCIAL MARKETS 0.00% of their portfolio | 6 $14 | Unchanged |
| IFG Advisory, LLC 0.00% of their portfolio | 6 $14 | New |
| Tidemark, LLC 0.00% of their portfolio | 2 $5 | Unchanged |